Table III.

SNP analysis by ELAC2 genotypes

SNP	0 copies		1 copy		2 copies		P-value*
	Case/control	OR	Case/control	OR (95% CI)	Case/control	OR (95% CI)
All prostate cancer
Snp1	428/447	1.00	198/186	1.11 (0.87–1.41)	21/12	1.82 (0.89–3.75)	0.20
Snp2	288/314	1.00	293/272	1.18 (0.94–1.49)	64/59	1.19 (0.80–1.75)	0.33
Snp3	179/161	1.00	328/330	0.89 (0.69–1.16)	133/146	0.82 (0.60–1.13)	0.46
Snp4	376/370	1.00	223/237	0.93 (0.73–1.17)	44/36	1.21 (0.76–1.92)	0.52
Snp5	308/296	1.00	263/280	0.90 (0.71–1.13)	72/68	1.01 (0.70–1.46)	0.63
Snp6	480/472	1.00	152/157	0.95 (0.73–1.22)	9/10	0.89 (0.36–2.22)	0.89
Snp8	472/487	1.00	164/149	1.13 (0.88–1.46)	9/8	1.16 (0.44–3.03)	0.63
Sporadic prostate cancer
Snp1	418/440	1.00	193/183	1.10 (0.87–1.41)	21/12	1.84 (0.89–3.78)	0.20
Snp2	280/312	1.00	287/265	1.21 (0.96–1.53)	63/58	1.21 (0.82–1.79)	0.23
Snp3	178/159	1.00	320/325	0.88 (0.68–1.14)	127/143	0.80 (0.58–1.10)	0.36
Snp4	369/363	1.00	216/234	0.91 (0.72–1.15)	43/36	1.18 (0.74–1.88)	0.49
Snp5	301/293	1.00	258/274	0.91 (0.72–1.15)	69/67	1.00 (0.69–1.45)	0.73
Snp6	471/466	1.00	147/154	0.94 (0.72–1.22)	8/9	0.91 (0.35–2.38)	0.87
Snp8	458/478	1.00	163/148	1.14 (0.88–1.48)	9/8	1.16 (0.44–3.04)	0.59

*P-value was for testing the null hypothesis: OR_{1 copy} = OR_{2 copies} = 1.